There are other lymphocyte-depleting agents used in humans outside of CVD: blinatumomab (Figure 2) targets CD19, which is expressed on both plasma cells and B1 subsets20; both are known to be atheroprotective.1,3 Therefore, targeting CD19 is unlikely to be beneficial in atherosclerosis. This evidence concerns the gene CD19 and atherosclerosis.